RGD Reference Report - DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma.

Authors: Fackler, MJ  McVeigh, M  Evron, E  Garrett, E  Mehrotra, J  Polyak, K  Sukumar, S  Argani, P 
Citation: Fackler MJ, etal., Int J Cancer. 2003 Dec 20;107(6):970-5.
RGD ID: 2289156
Pubmed: PMID:14601057   (View Abstract at PubMed)
DOI: DOI:10.1002/ijc.11508   (Journal Full-text)

Little is known about epigenetic silencing of genes by promoter hypermethylation in lobular breast cancers. The promoter methylation status of 5 cancer-related genes (RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist) was evaluated in 2 types of lobular cancers, in situ (LCIS) and invasive lobular carcinomas (ILC) (n = 32), and compared to ductal in situ (DCIS) and invasive (IDC) breast cancers (n = 71). By using methylation-specific PCR (MSP), 100% of ILC and 69% of LCIS cases were found to have 1 or more hypermethylated genes among the panel of 5 genes (compared to 100% IDC and 95% of DCIS). Two or more hypermethylated genes were detected per tumor in 79% of invasive and 61% of in situ lobular carcinomas compared to 81% of IDC and 77% of DCIS. By contrast, DNA from nearly all normal reduction mammoplasty tissues (n = 8) was unmethylated for the 5 genes. The methylation profiles of lobular vs. ductal carcinomas with respect to RASSF1A, Cyclin D2, RARbeta, and Hin-1 genes were similar, suggesting that gene silencing by promoter hypermethylation is likely to be important in both groups of diseases. Distinctly different, Twist was hyper- methylated less often in ILC (16%, 3/19 cases) than in IDC (56%, 15/27 cases) (p = 0.01). These results suggest that these 2 types of tumors share many common methylation patterns and some molecular differences. Additional studies might lend further understanding into the etiology and clinical behavior of this tumor type.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
CCND2Humanductal carcinoma in situ  IDA DNA:hypermethylation:promoter and breastRGD 
Ccnd2Ratductal carcinoma in situ  ISOCCND2 (Homo sapiens)DNA:hypermethylation:promoter and breastRGD 
Ccnd2Mouseductal carcinoma in situ  ISOCCND2 (Homo sapiens)DNA:hypermethylation:promoter and breastRGD 
CCND2Humaninvasive lobular carcinoma  IDA DNA:hypermethylation:promoter and breastRGD 
Ccnd2Ratinvasive lobular carcinoma  ISOCCND2 (Homo sapiens)DNA:hypermethylation:promoter and breastRGD 
Ccnd2Mouseinvasive lobular carcinoma  ISOCCND2 (Homo sapiens)DNA:hypermethylation:promoter and breastRGD 

Objects Annotated

Genes (Rattus norvegicus)
Ccnd2  (cyclin D2)

Genes (Mus musculus)
Ccnd2  (cyclin D2)

Genes (Homo sapiens)
CCND2  (cyclin D2)


Additional Information